What We Build.
And Why It Matters.
SymbAIo builds adaptive intelligence for people navigating complex human experiences. Our work spans two connected but distinct entities: SymbAIo Inc. — the parent company and owner of the Signature Suite — and SymbAIo Labs, our client-facing innovation studio.
Intelligence That Serves People
We design, build, and deploy intelligence systems for moments where precision, privacy, and human dignity are non-negotiable. Every system we create is grounded in the same principle: the human is the authority.
Human-Led Intelligence
We build adaptive intelligence systems for the moments that matter most — chronic illness, survival, safety, and the complex human experiences that current technology ignores.
Proprietary Architecture
Every product in the Signature Suite runs on mønk™, our proprietary intelligence engine. Claude by Anthropic powers the AI infrastructure beneath it — our provider of choice for safety, interpretability, and sovereignty.
Trauma-Informed by Design
Our systems are built with structural safety at the architecture level — not just sensitivity in the language. Every design decision begins with the question: could this be weaponized?
Signal Processing & Biomarkers
We transform wearable biomarker data into traceable, correlative intelligence. Heart rate variability, sleep patterns, stress signatures — the signals the body produces that current technology reduces to dashboards.
Survivor Intelligence
Technology designed for people navigating psychological violence and coercive control. We build awareness systems — not surveillance systems — that return the body's intelligence to the individual.
Enterprise & Integration
Complex system integration across healthcare, enterprise, and consumer technology stacks. From concept to architecture to market — grounded in technical feasibility and human need.
Two Entities. One Mission.
SymbAIo Inc.
The parent company. Incorporated in Delaware, USA (October 2025). SymbAIo Inc. owns and develops the Signature Suite — a proprietary ecosystem of intelligence products built on mønk™, our foundational AI engine.
The Signature Suite — including iMpatient™, K@te™, mønk™, and iMpulSIM™ — is the sole intellectual property of SymbAIo Inc.
SymbAIo Labs
Our client-facing innovation studio. SymbAIo Labs builds custom AI-powered tools, platforms, and intelligence systems for external clients — from solopreneurs and small businesses to enterprise partners.
Labs clients receive bespoke solutions powered by Claude (our AI provider of choice), designed with the same human-led principles that define the Signature Suite. The full SymbAIo Labs portfolio and client showcase will live on its own dedicated site.
The Signature Suite
Four proprietary products. One intelligence engine. All owned and developed exclusively by SymbAIo Inc.
iMpatient™
Launching May 30, 2026Patient-first health intelligence. Wearable biomarker integration, correlative health blueprints, and provider-ready insight summaries.
K@te™
Launching November 2026Contextual safety companion for survivors of psychological violence and coercive control. Biomarker-driven awareness, powered by mønk™.
mønk™
BETASymbAIo's proprietary intelligence engine. The foundational architecture beneath every product in the Signature Suite.
iMpulSIM™
USPTO Patent ReviewSignal processing engine that identifies meaningful patterns in complex data streams before they become actionable crises.
The Journey
Signature Suite architecture defined
Five-product ecosystem designed: iMpatient™, K@te™, iMpulSIM™, mønk™, NeuroSPARK™.
SymbAIo Inc. formed as Delaware C-Corp
Founded by Azure Antoinette — poet, TED Speaker, and self-taught developer — to build human-led intelligence platforms.
Pre-Seed fundraising initiated
Investor portal and data room established. $3.2M raise at $25M valuation. Building toward MVP.
iMpatient™ development accelerated
Core biomarker integration and pattern recognition engine in active development. mønk™ enters BETA, powering test versions.
iMpatient™ launches
Consumer launch of the patient-first health intelligence platform. Wearable biomarker integration, correlative health blueprints, and provider-ready insight summaries go live.
K@te™ launches
K@te™ enters the market — a contextual safety companion for survivors of psychological violence and coercive control. Biomarker-driven awareness, powered by the mønk™ engine.
Want to see the full picture?
Detailed technical documentation, product roadmaps, and investment materials are available in the Investor Portal.